Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 7/20 | 0.64 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.64 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.64 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | HTR1A | P08908 | 1/20 | 0.49 |
| ▸ | THPO | P40225 | 1/20 | 0.49 |
| ▸ | BLM | P54132 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | NMUR2 | Q9GZQ4 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.49 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CNR1 | P21554 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | HRH1 | P35367 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12165438 | 1.00 | SLC6A2 (0.64) | SLC6A2SLC6A4SLC6A3OPRM1ALDH1A1 | |
| SCHEMBL13657720 | 0.88 | SLC6A2 (0.51) | SLC6A2SLC6A4SLC6A3OPRM1LMNA | |
| SCHEMBL10613760 | 0.86 | SLC6A2 (0.47) | SLC6A2SLC6A4SLC6A3OPRM1 | |
| SCHEMBL12165445 | 0.85 | SLC6A2 (0.47) | SLC6A2SLC6A4SLC6A3OPRM1LMNA | |
| SCHEMBL12165440 | 0.85 | SLC6A2 (0.47) | SLC6A2SLC6A4SLC6A3OPRM1LMNA | |
| N-Desmethylvenlafaxine SCHEMBL5435875 | 0.84 | SLC6A2 (0.67) | SLC6A2SLC6A4SLC6A3OPRM1LMNA | |
| SCHEMBL14598890 | 0.84 | SLC6A4 (0.46) | SLC6A2SLC6A4SLC6A3OPRM1ALDH1A1 | |
| N-Desmethylvenlafaxine SCHEMBL5439972 | 0.84 | SLC6A2 (0.67) | SLC6A2SLC6A4SLC6A3OPRM1LMNA | |
| N-Desmethylvenlafaxine SCHEMBL734652 | 0.84 | SLC6A2 (0.67) | SLC6A2SLC6A4SLC6A3OPRM1LMNA | |
| SCHEMBL14227832 | 0.81 | SLC6A2 (0.56) | SLC6A2SLC6A4SLC6A3OPRM1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2621891-B1 | POLYMORPHS OF 4-[2-DIMETHYLAMINO-1-(1-HYDROXYCYCLOHEXYL)ETHYL]PHENYL 4-METHYLBENZOATE HYDROCHLORIDE, METHODS FOR PREPARING THE SAME AND USE OF THE SAME | SHAN DONG LUYE PHARM CO LTD (CN) | 2019-11-06 | — | — | EP | disclosed |
| EP-1897867-B1 | COMPOUNDS USED FOR INTERRUPTING REUPTAKE OF 5-HYDROXYTRYPTAMINE AND NOREPINEPHRINE OR TREATING DISEASES SUCH AS DEPRESSION | Shandong luye pharmaceutical co ltd (CN) | 2017-02-15 | — | — | EP | disclosed |
| EP-1897867-B1 | COMPOUNDS USED FOR INTERRUPTING REUPTAKE OF 5-HYDROXYTRYPTAMINE AND NOREPINEPHRINE OR TREATING DISEASES SUCH AS DEPRESSION | Shandong luye pharmaceutical co ltd (CN) | 2017-02-15 | — | — | EP | disclosed |
| US-9199912-B2 | Polymorphs of 4-[2-dimethylamino-1-(1-hydroxycyclohexyl)ethyl]phenyl 4-methylbenzoate hydrochloride, methods of preparing the same and use of the same | SHANDONG LUYE PHARMACEUTICAL CO., LTD. (CN) | 2015-12-01 | — | — | US | disclosed |
| US-9199912-B2 | Polymorphs of 4-[2-dimethylamino-1-(1-hydroxycyclohexyl)ethyl]phenyl 4-methylbenzoate hydrochloride, methods of preparing the same and use of the same | SHANDONG LUYE PHARMACEUTICAL CO., LTD. (CN) | 2015-12-01 | — | — | US | disclosed |
| US-9199912-B2 | Polymorphs of 4-[2-dimethylamino-1-(1-hydroxycyclohexyl)ethyl]phenyl 4-methylbenzoate hydrochloride, methods of preparing the same and use of the same | SHANDONG LUYE PHARMACEUTICAL CO., LTD. (CN) | 2015-12-01 | — | — | US | disclosed |
| US-20150299102-A1 | DERIVATIVES OF (-)-VENLAFAXINE AND METHODS OF PREPARING AND USING THE SAME | SUNOVION PHARMACEUTICALS INC (US) | 2015-10-22 | — | — | US | disclosed |
| US-20150299102-A1 | DERIVATIVES OF (-)-VENLAFAXINE AND METHODS OF PREPARING AND USING THE SAME | SUNOVION PHARMACEUTICALS INC (US) | 2015-10-22 | — | — | US | disclosed |
| US-20150299102-A1 | DERIVATIVES OF (-)-VENLAFAXINE AND METHODS OF PREPARING AND USING THE SAME | SUNOVION PHARMACEUTICALS INC (US) | 2015-10-22 | — | — | US | disclosed |
| US-9072700-B2 | Methods of using derivatives of (−)-venlafaxine | SUNOVION PHARMACEUTICALS INC. (US) | 2015-07-07 | — | — | US | disclosed |
| US-20040180952-A1 | Derivatives of (-)- and (+)-venlafaxine and methods of preparing and using the same | SEPRACOR INC. | 2004-09-16 | — | — | US | disclosed |
| US-20040106576-A1 | Derivatives of venlafaxine and methods of preparing and using the same | SEPRACOR INC. (US) | 2004-06-03 | — | — | US | disclosed |
| US-20030083338-A1 | Compositions and methods for management of serotonin-mediated disorders | SEPRACOR, INC. | 2003-05-01 | — | — | US | disclosed |
| US-20030018083-A1 | Methods of treating and preventing pain, anxiety, and incontinence using derivatives of (-)-venlafaxine | SEPRACOR, INC. | 2003-01-23 | — | — | US | disclosed |
| US-6441048-B1 | A (-)VENLAFAXINE DERIVATIVE OR A SALT FREE OF ITS (+)STEREO-ISOMER AND A CARRIER OR EXCIPIENT; SIDE EFFECT REDUCTION; ANTIDEPRESSANTS; ATTENTION DEFICIT DISORDER; HYPERACTIVITY. OBESITY; INHIBITION OF NEURONAL MONOAMINE REUPTAKE | SEPRACOR, INC. | 2002-08-27 | — | — | US | disclosed |
| US-20020086904-A1 | Methods of treating affective disorders using derivatives of (-)- venlafaxine | SEPRACOR INC. | 2002-07-04 | — | — | US | disclosed |
| US-6342533-B1 | ANTIDEPRESSANTS UDES FOR BIPOLAR AND ATTENTION DEFICIT DISORDERS, HYPERACTIVITY, PARKINSON'S DISEASE, EPILEPSY, EATING DISORDERS | SEPRACOR, INC. | 2002-01-29 | — | — | US | disclosed |
| EP-1165487-A1 | DERIVATIVES OF VENLAFAXINE AND METHODS OF PREPARING AND USING THE SAME | Sepracor Inc. (US) | 2002-01-02 | — | — | EP | disclosed |
| US-6197828-B1 | NONTRICYCLIC ANTIDEPRESSANTS HAVE RECENTLY BEEN DEVELOPED THAT DIMINISH THE CARDIOVASCULAR AND ANTICHOLINERGIC LIABILITY, | SEPRACOR, INC. | 2001-03-06 | — | — | US | disclosed |
| WO-2000059851-A1 | DERIVATIVES OF VENLAFAXINE AND METHODS OF PREPARING AND USING THE SAME | SEPRACOR INC. (US) | 2000-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180952-A1 | Derivatives of (-)- and (+)-venlafaxine and methods of preparing and using the same | COMT, MAOA, MAOB | SLC6A2 4/4885SLC6A4 14/4885SLC6A3 5/4885 |
| US-20030018083-A1 | Methods of treating and preventing pain, anxiety, and incontinence using derivatives of (-)-venlafaxine | COMT, MAOA, ACHE | SLC6A2 4/4885SLC6A4 13/4885SLC6A3 6/4885 |
| US-20150299102-A1 | DERIVATIVES OF (-)-VENLAFAXINE AND METHODS OF PREPARING AND USING THE SAME | COMT, MAOA, MAOB | SLC6A2 4/4885SLC6A4 11/4885SLC6A3 5/4885 |
| US-20020086904-A1 | Methods of treating affective disorders using derivatives of (-)- venlafaxine | COMT, MAOA, MAOB | SLC6A2 4/4885SLC6A4 11/4885SLC6A3 6/4885 |
| US-20030083338-A1 | Compositions and methods for management of serotonin-mediated disorders | HTR5A, TPH1, HTR4 | SLC6A2 24/4885SLC6A4 12/4885SLC6A3 40/4885 |
| US-20040106576-A1 | Derivatives of venlafaxine and methods of preparing and using the same | COMT, MAOA, MAOB | SLC6A2 4/4885SLC6A4 13/4885SLC6A3 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.